Granted Patent
B2
US 12,220,415 · App. 16/975,818 · Granted Feb 11, 2025
WEE1 kinase inhibitors and methods of treating cancer using the same
Inventors:
Philip Reigan (Denver, CO); Donald S. Backos (Aurora, CO); Christopher J. Matheson (Denver, CO); Kimberly A. Casalvieri (Denver, CO)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A compound, or a pharmaceutically acceptable salts or prodrugs thereof, having the chemical structure: and methods of using these compounds to inhibit WEE1 kinase and treat cancer in a subject.
Claims (22)
1. A compound having the chemical structure:
or a pharmaceutically acceptable salt thereof, wherein:
R 1 is 3 -(2-hydroxypropan-2-yl) phenyl or 6-(2-hydroxypropan-2-yl) pyridin-2-yl;
R 2 is allyl, methyl, ethyl, propyl, isopropyl, butyl, or isobutyl;
R 3 is O;
R 4 is NR 7 R 8 ;
R 7 and R 8 each are independently H or 4-(2 (dimethylamino) ethyl) phenyl); and wherein
R 7 and R 8 are not simultaneously H.
2. A compound being selected from:
3. The compound of claim 2 , being:
4. The compound of claim 2 , being:
5. The compound of claim 2 , being:
6. The compound of claim 2 , being:
7. The compound of claim 2 , being:
8. The compound of claim 2 , being:
9. The compound of claim 2 , being:
10. The compound of claim 2 , being:
11. The compound of claim 2 , being:
12. A pharmaceutical composition comprising the compound of claim 1 , and at least one pharmaceutically acceptable additive.
13. A pharmaceutical kit containing the pharmaceutical composition of claim 12 , prescribing information for the composition, and a container.
14. The compound of claim 2 , being:
15. The compound of claim 2 , being:
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 25, 2021
From: REIGAN, PHILIP; BACKOS, DONALD S.; MATHESON, CHRISTOPHER J.; CASALVIERI, KIMBERLY A.
To: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Reel/Frame 056341/0214 →
Continuity (2)
Provisional Application
62636831
· Feb 28, 2018
References Cited (50)
US 8791125B2
· Sagara
· 2014
[cited by examiner]
US 9073916B2
· Smaill
· 2015
[cited by examiner]
US 20160031877A1
· Smaill et al.
· 2016
[cited by applicant]
GB 884151A
· 1961
[cited by applicant]
JP 2013503859A
· 2013
[cited by applicant]
JP 2020505356A
· 2020
[cited by applicant]
JP 2020510630A
· 2020
[cited by applicant]
JP 2020529993A
· 2020
[cited by applicant]
WO WO2006091737A1
· 2006
[cited by applicant]
WO WO2007126122A1
· 2007
[cited by applicant]
WO WO2007126128A1
· 2007
[cited by applicant]
WO WO2015092431A1
· 2015
[cited by applicant]
WO WO2017075629A2
· 2017
[cited by applicant]
WO WO2018133829A1
· 2018
[cited by applicant]
WO WO2019028008A1
· 2019
[cited by examiner]
WO WO2019169065A2
· 2019
[cited by applicant]
A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells Matheson et al. ACS Chem. Biol. 2016, 11, 921-930 (Year: 2016).
[cited by examiner]
Bridges K.A. et al. “MK-1775, a Novel Weel Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells”, Clinical Cancer Research 2011,17(17):5638-5648.
[cited by applicant]
Bucher N. et al. “G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer”, British Journal of Cancer, 2008, 98(3):523-528.
[cited by applicant]
Chen T. et al. “Targeting the S and G2 checkpoint to treat cancer”, Drug Discovery Today, 2012; 17(5-6):194-202.
[cited by applicant]
De Witt Hamer P.C. et al. “WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe”, Clinical Cancer Research, 2011,17(13):4200-4207.
[cited by applicant]
Do K. et al. “Weel kinase as a target for cancer therapy”, Cell Cycle, 2013, 12(19):3159-3164.
[cited by applicant]
Forte S. et al. “Gene Expression Analysis of PTEN Positive Glioblastoma Stem Cells Identifies DUB3 and Weel Modulation in a Cell Differentiation Model”, PLoS One 2013, 8(12):e81432.
[cited by applicant]
Harris E.S. et al. “Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma”, Molecular Cancer, 2014, 13:72.
[cited by applicant]
Hirai H. et al. “Small-molecule inhibition of Weel kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents”, Molecular Cancer Therapy, 2009, 8(11):2992-3000.
[cited by applicant]
Hirai H. et al. “MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNAdamaging agents, including 5-fluorouracil”, 2010, 9(7):514-522.
[cited by applicant]
Igarashi M et al. “Wee1+-like gene in human cells”, Letters to Nature, 1991, 353(6339):80-83.
[cited by applicant]
Indovina P. et al. “Targeting the checkpoint kinase WEE1: Selective sensitization of cancer cells to DNA-damaging drugs”, Cancer Biology & Therapy, 2010 9(7):523-525.
[cited by applicant]
Jin P. et al. “Role of Inhibitory CDC2 Phosphorylation in Radiation-induced G2 Arrest in Human Cells”, The Journal of Cell Biology, 1996,134(4):963-970.
[cited by applicant]
Leijen S et al. “Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging Agents”, Current Clinical Pharmacology, 2010, 5(3):186-191.
[cited by applicant]
McGowan C. H. et al. “Human Weel kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15”, The EMBO Journal, 1993, 12(1):75-85.
[cited by applicant]
Mir S.E. et al. “In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in Glioblastoma”, Cancer Cell, 2010, 18(3):244-257.
[cited by applicant]
O'Conner, LJ et al., “Efficient synthesis of 2-nitroimidazole derivatives and the bioreductive clinical candidate Evofosfamide (TH-302)”, Organic Chemistry Frontiers 2015, 2, pp. 1-4 (1026-1029).
[cited by applicant]
Orgogozo et al. “Thedifferentialviewofgenotype—phenotyperelationships”, Frontiers in Genetics, Hypothesis and Theory, 2015, 6:70.
[cited by applicant]
Parker L. L. et al. “Inactivation of the p34cdc2-Cyclin B Complex by the Human WEE1 Tyrosine Kinase”, Science, 1992, 257(5078):1955-1957.
[cited by applicant]
Tanabe, K. et al., “Current molecular design of intelligent drugs and imaging probes targeting tumor-specific microenvironments”, Organic & Biomolecular Chemistry, 2007, 5:3745-3757.
[cited by applicant]
Tercel, M. et al., “Hypoxia-Selective Antitumor Agents. 16. Nitroarylmethyl Quaternary Salts—as Bioreductive Prodrugs of the Alkylating Agent Mechlorethamine”, Journal of Medicinal Chemistry, 2001, 44(21): 3511-3522.
[cited by applicant]
Tuel-Ahlgren et al. “Role of Tyrosine Phosphorylation in Radiation—Induced Cell Cycle—Arrest of Leukemic B-Cell Precursors at the G2-M Transition Checkpoint”, Leukemia & Lymphoma 1996, 20(5-6):417-426.
[cited by applicant]
Wang et al. “Global Profiling of Signaling Networks: Study of Breast Cancer Stem Cells and Potential Regulation”, The Oncologist, 2011, 16(7):966-979.
[cited by applicant]
Zhou et al. “A regimen combining the Weel inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations”, Leukemia, 2015, 29(4):807-818.
[cited by applicant]
Van Linden et al. “Inhibition of Wee1 Sensitizes Cancer Cells to Antimetabolite Chemotherapeutics In Vitro and In Vivo, Independent of p53 Functionality”, Molecular Cancer Therapeutics, 2013, 12(12):2675-2684.
[cited by applicant]
Matheson C. J. et al. “Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy”, ChemMedChem Communications, vol. 13, No. 16, 2018, pp. 1681-1694.
[cited by applicant]
Hauser et al., “Pyrazolono (3, 4-d) pyrimidines. II. 6-Methylpyrazolono (3, 4-d) pyrimidines and Some Reactions of Pyrazolono (3, 4-d) pyrimidines1, 2”. The Journal of Organic Chemistry. Feb. 1961; 26(2): 451-5.
[cited by applicant]
Shen et al., “3-aminopyrazolopyrazine Derivatives as Spleen Tyrosine Kinase Inhibitors,” Chemical Biology & Drug Design. Nov. 2016; 88(5): 690-8.
[cited by applicant]
Office Action dated Jan. 24, 2024 in Australian Patent Application No. 2019227823.
[cited by applicant]
Office Action dated Oct. 30, 2023 in Japanese Patent Application No. 2020-545351.
[cited by applicant]
Office Action dated Apr. 4, 2024 in Canadian Patent Application No. 3,088,997.
[cited by applicant]